Cargando…

Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape

BACKGROUND: Human mesenchymal cells are culprit factors in vascular (patho)physiology and are hallmarked by phenotypic and functional heterogeneity. At present, they are subdivided by classic umbrella terms, such as “fibroblasts,” “myofibroblasts,” “smooth muscle cells,” “fibrocytes,” “mesangial cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruijn, Laura E., van den Akker, Brendy E. W. M., van Rhijn, Connie M., Hamming, Jaap F., Lindeman, Jan H. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763765/
https://www.ncbi.nlm.nih.gov/pubmed/33190596
http://dx.doi.org/10.1161/JAHA.120.017094
_version_ 1783628096051609600
author Bruijn, Laura E.
van den Akker, Brendy E. W. M.
van Rhijn, Connie M.
Hamming, Jaap F.
Lindeman, Jan H. N.
author_facet Bruijn, Laura E.
van den Akker, Brendy E. W. M.
van Rhijn, Connie M.
Hamming, Jaap F.
Lindeman, Jan H. N.
author_sort Bruijn, Laura E.
collection PubMed
description BACKGROUND: Human mesenchymal cells are culprit factors in vascular (patho)physiology and are hallmarked by phenotypic and functional heterogeneity. At present, they are subdivided by classic umbrella terms, such as “fibroblasts,” “myofibroblasts,” “smooth muscle cells,” “fibrocytes,” “mesangial cells,” and “pericytes.” However, a discriminative marker‐based subclassification has to date not been established. METHODS AND RESULTS: As a first effort toward a classification scheme, a systematic literature search was performed to identify the most commonly used phenotypical and functional protein markers for characterizing and classifying vascular mesenchymal cell subpopulation(s). We next applied immunohistochemistry and immunofluorescence to inventory the expression pattern of identified markers on human aorta specimens representing early, intermediate, and end stages of human atherosclerotic disease. Included markers comprise markers for mesenchymal lineage (vimentin, FSP‐1 [fibroblast‐specific protein‐1]/S100A4, cluster of differentiation (CD) 90/thymocyte differentiation antigen 1, and FAP [fibroblast activation protein]), contractile/non‐contractile phenotype (α‐smooth muscle actin, smooth muscle myosin heavy chain, and nonmuscle myosin heavy chain), and auxiliary contractile markers (h1‐Calponin, h‐Caldesmon, Desmin, SM22α [smooth muscle protein 22α], non‐muscle myosin heavy chain, smooth muscle myosin heavy chain, Smoothelin‐B, α‐Tropomyosin, and Telokin) or adhesion proteins (Paxillin and Vinculin). Vimentin classified as the most inclusive lineage marker. Subset markers did not separate along classic lines of smooth muscle cell, myofibroblast, or fibroblast, but showed clear temporal and spatial diversity. Strong indications were found for presence of stem cells/Endothelial‐to‐Mesenchymal cell Transition and fibrocytes in specific aspects of the human atherosclerotic process. CONCLUSIONS: This systematic evaluation shows a highly diverse and dynamic landscape for the human vascular mesenchymal cell population that is not captured by the classic nomenclature. Our observations stress the need for a consensus multiparameter subclass designation along the lines of the cluster of differentiation classification for leucocytes.
format Online
Article
Text
id pubmed-7763765
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77637652020-12-28 Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape Bruijn, Laura E. van den Akker, Brendy E. W. M. van Rhijn, Connie M. Hamming, Jaap F. Lindeman, Jan H. N. J Am Heart Assoc Systematic Review and Meta‐analysis BACKGROUND: Human mesenchymal cells are culprit factors in vascular (patho)physiology and are hallmarked by phenotypic and functional heterogeneity. At present, they are subdivided by classic umbrella terms, such as “fibroblasts,” “myofibroblasts,” “smooth muscle cells,” “fibrocytes,” “mesangial cells,” and “pericytes.” However, a discriminative marker‐based subclassification has to date not been established. METHODS AND RESULTS: As a first effort toward a classification scheme, a systematic literature search was performed to identify the most commonly used phenotypical and functional protein markers for characterizing and classifying vascular mesenchymal cell subpopulation(s). We next applied immunohistochemistry and immunofluorescence to inventory the expression pattern of identified markers on human aorta specimens representing early, intermediate, and end stages of human atherosclerotic disease. Included markers comprise markers for mesenchymal lineage (vimentin, FSP‐1 [fibroblast‐specific protein‐1]/S100A4, cluster of differentiation (CD) 90/thymocyte differentiation antigen 1, and FAP [fibroblast activation protein]), contractile/non‐contractile phenotype (α‐smooth muscle actin, smooth muscle myosin heavy chain, and nonmuscle myosin heavy chain), and auxiliary contractile markers (h1‐Calponin, h‐Caldesmon, Desmin, SM22α [smooth muscle protein 22α], non‐muscle myosin heavy chain, smooth muscle myosin heavy chain, Smoothelin‐B, α‐Tropomyosin, and Telokin) or adhesion proteins (Paxillin and Vinculin). Vimentin classified as the most inclusive lineage marker. Subset markers did not separate along classic lines of smooth muscle cell, myofibroblast, or fibroblast, but showed clear temporal and spatial diversity. Strong indications were found for presence of stem cells/Endothelial‐to‐Mesenchymal cell Transition and fibrocytes in specific aspects of the human atherosclerotic process. CONCLUSIONS: This systematic evaluation shows a highly diverse and dynamic landscape for the human vascular mesenchymal cell population that is not captured by the classic nomenclature. Our observations stress the need for a consensus multiparameter subclass designation along the lines of the cluster of differentiation classification for leucocytes. John Wiley and Sons Inc. 2020-11-16 /pmc/articles/PMC7763765/ /pubmed/33190596 http://dx.doi.org/10.1161/JAHA.120.017094 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Systematic Review and Meta‐analysis
Bruijn, Laura E.
van den Akker, Brendy E. W. M.
van Rhijn, Connie M.
Hamming, Jaap F.
Lindeman, Jan H. N.
Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape
title Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape
title_full Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape
title_fullStr Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape
title_full_unstemmed Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape
title_short Extreme Diversity of the Human Vascular Mesenchymal Cell Landscape
title_sort extreme diversity of the human vascular mesenchymal cell landscape
topic Systematic Review and Meta‐analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763765/
https://www.ncbi.nlm.nih.gov/pubmed/33190596
http://dx.doi.org/10.1161/JAHA.120.017094
work_keys_str_mv AT bruijnlaurae extremediversityofthehumanvascularmesenchymalcelllandscape
AT vandenakkerbrendyewm extremediversityofthehumanvascularmesenchymalcelllandscape
AT vanrhijnconniem extremediversityofthehumanvascularmesenchymalcelllandscape
AT hammingjaapf extremediversityofthehumanvascularmesenchymalcelllandscape
AT lindemanjanhn extremediversityofthehumanvascularmesenchymalcelllandscape